Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | GPR3 | P46089 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610385 | 0.80 | FFAR4 (0.46) | KIF11CES1FFAR4GPR3BCHE | |
| SCHEMBL30540027 | 0.80 | FFAR4 (0.46) | KIF11CES1FFAR4GPR3BCHE | |
| SCHEMBL30567116 | 0.78 | GPR3 (0.41) | KIF11CES1FFAR4GPR3WDR5 | |
| SCHEMBL2437670 | 0.78 | GPR3 (0.41) | KIF11CES1FFAR4GPR3WDR5 | |
| SCHEMBL1198803 | 0.78 | TRPV4 (0.49) | KIF11CES1FFAR4GPR3WDR5 | |
| SCHEMBL2502219 | 0.77 | TRPV4 (0.57) | KIF11CES1CHRM5TRPV4 | |
| SCHEMBL3691567 | 0.76 | WDR5 (0.43) | KIF11CES1FFAR4GPR3WDR5 | |
| SCHEMBL15212079 | 0.76 | FFAR4 (0.46) | KIF11CES1FFAR4GPR3BCHE | |
| SCHEMBL29948961 | 0.76 | WDR5 (0.43) | KIF11CES1FFAR4GPR3WDR5 | |
| SCHEMBL10964642 | 0.74 | CES1 (0.41) | KIF11CES1FFAR4GPR3WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | KIF11 4418/4885CES1 3264/4885FFAR4 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.